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Abstract
Background: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel
networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European
Commission’s Article 29 Working Party stated that geolocation information is personal data.
To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database
to find an optimal privacy method.
Methods: Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November
2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise
addition (randomization) and k-anonymity (generalization).
Results: Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.
5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity
using MASK data to protect the users’ life privacy.
Discussion: k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for
other databases.
Keywords: Anonymization, App, MASK, Rhinitis, Asthma
* Correspondence: jean.bousquet@orange.fr
63Euforea, Brussels, Belgium
70INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public
health approaches, Villejuif, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Samreth et al. World Allergy Organization Journal  (2018) 11:15 
https://doi.org/10.1186/s40413-018-0194-3
Background
MASK-rhinitis (Mobile Airways Sentinel networK for al-
lergic rhinitis) is a patient- centered ICT (Information and
Communication Technology) system [1]. A mobile phone
app (the Allergy Diary App), central to MASK, is available
in 22 countries. It has been validated [2] and found to be
an easy and effective method of assessing the symptoms
of allergic rhinitis (AR) and work productivity [2–5].
MASK follows the checklist for the evaluation of Good
Practices developed by the European Union Joint Action
JA-CHRODIS (Joint Action on Chronic Diseases and Pro-
moting Healthy Ageing across the Life Cycle) [6].
The major aims of MASK are to provide care pathways
[7] in rhinitis and asthma multimorbidity [8] including a
sentinel network using the geolocation of users [9] and to
inform the App user of the pollen and/or pollution risk
level in their area, by means of geolocation. Both of these
functionalities are being developed.
European data protection law
The European data protection law only applies to personal
data, i.e. “any information relating to an identified or iden-
tifiable natural person; an identifiable natural person is
one who can be identified, directly or indirectly, in par-
ticular by reference to an identifier such as a name, an
identification number, location data, an online identifier
or to one or more factors specific to the physical, physio-
logical, genetic, mental, economic, cultural or social iden-
tity of that natural person” (Art. 4 para. 1 no. 1 GDPR)
[10]. Data anonymization is a method of sanitization for
privacy. Anonymization renders personal data “in such a
manner that the data subject is not or no longer identifi-
able.” (Recital 26 GDPR) [11]. As anonymous or anon-
ymized data lack identifiability, anonymization principally
enables the sharing of data in a way that preserves privacy
with minimal data loss.
In 2014, lacking a clear statement within the law, the
European Commission’s Article 29 Working Party
(WP29) stated, with regards to the Directive 95/46/EC
[12], that geolocation information is not only personal data
but also to be considered as an identifier itself [13, 14]. This
WP29 finding has become indisputable as the General Data
Protection Regulation now clearly states within its defin-
ition of personal data (Art. 4 para. 1 no. 1 GDPR) that loca-
tion data serves as an identifier.
Processing personal data legally under the European
Data Protection Law first requires an assessment of the
applicable law. Under the framework of Directive 95/46/
EC [12], the situation was complex as the Directive may
be implemented differently by the Member States of the
European Union. Depending on the context of processing,
compliance with additional legislation may be required.
Processing personal data by means of an app, such as
the Allergy Diary App, is under the Directive 95/46/EC
[12] and Directive 2002/58/EC [15] as amended by the Dir-
ective 2009/136/EC [16].
Since May 2018, the situation has become more strin-
gent as the General European Data Protection Regula-
tion now applies and all general national provisions on
processing personal data are being overruled by Euro-
pean Law. Directive 2002/58/EC [15], as amended by
Directive 2009/136/EC [17], is currently being revised
and will also be replaced by a Regulation.
Processing personal data lawfully therefore requires
(Art. 4 GDPR) either the data subject’s consent or any
other legal ground being applied. Principally, such pro-
cessing is unequivocally necessary for the performance
of the service or contract concerned. For electronic
communication services, such as apps, Directive 2002/
58/EC [15] as amended by Directive 2009/136/EC [16]
provides additional requirements.
Data on a subject’s smart device may only be accessed
further to consent, (Article 5 para. 3 Directive 2002/58/
EC [15] as amended by Directive 2009/136/EC) [16].
Such consent for technical access has to be distinguished
from the potential legal ground on processing personal
data [18]. Given the high sensitivity of location data, as
highlighted by the clarification in Article 4 GDPR and
multiple Opinions of the WP20 such as 00461/13/EN
WP202 and 0829/14/EN WP216, apps should only tech-
nically access and process location data after explicit
consent. The processing of personal data under data
protection law may however find its legal ground in Art-
icle 6 para. 1 lit. b or lit. f GDPR and therefore does not
require individual data subject’s consent in all
circumstances.
Publishing and sharing location data may however require
the data subject’s consent. As consent creates additional bur-
dens, the anonymization of such data seems an appropriate
option in providing a service like the Allergy Diary App.
Anonymization techniques are not all considered with the
same level of confidence [13, 14]. The data of the Allergy
Diary App are fully anonymous except for the data related
to geolocation. The two main data anonymization processes,
with differing strengths and weaknesses, are randomization
and generalization [19, 20]. The randomization approach in-
cludes noise addition [21] and differential confidentiality
[22]. k-anonymization [23–26] and its derivative processes
(l-diversity [27] and t-closeness [28]) are the most widely
accepted generalization approaches and are acceptable by
WP 29.
Methods
Aim and design
In order to assess whether the anonymized geolocation
level of the user of the MASK Allergy Diary is sufficient
for the analyses planned, a study was set up including all
people who had used the App from December 1st 2015 to
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November 30th 2017. Noise addition and k-anonymization
were evaluated.
Setting
The study included users from 22 countries who registered
with the Allergy Diary App -available in 16 languages-
through App stores. Geolocated data were retrieved from
the users' smartphone and collected in every country where
the App was available. This data retrieval was technically
independent of the App.
Participants
All consecutive users who registered with the Allergy
Diary were included if they agreed to be geolocated.
There were no exclusion criteria. Some of the users were
clinic patients who had been asked by their physician to
use the App. However, due to the anonymization of data,
no specific information could be gathered, as previously
described in detail [3, 4]. With their consent, five users
(3 from Kyomed and 2 from Peercode) were considered
as “testers” for the algorithm sensitivity analysis.
Ethics
The Allergy Diary is CE1 registered [3, 4]. No ethical
committee approval was needed for this study.
Allergy Diary App users agreed to be geolocated in the
“terms of use” and “privacy policy” of the Allergy Diary
App. Geolocation was optional, the user could allow it or
not on his/her mobile phone and it could remove it at any
time. Moreover, geolocation was not used in the data min-
ing process and the phone IP was not recorded. Finally,
the App functionalities were the same whether the user
was geolocated or not.
Outcomes reported in the allergy diary
Users assess their daily symptom control via the touchsc-
reen functionality on their smart phone. They were invited
to click on four consecutive visual analogue scales (VAS)
(global evaluation, nasal, ocular, asthma) [3, 4].
Geolocation of days reporting VAS
ISO/TC 211 standards are currently being used to deter-
mine precise position and location by means of coordinates
or geographic identifiers. The geolocation information ap-
pears as a set of two numbers corresponding to latitude
and longitude (Fig. 1).
Data analysis
We initially mapped the data in order to validate the fact
that the geolocation data of the App users is an identify-
ing process (https://folium.readthedocs.io/en/latest/). Ex-
periments have been conducted by using the Folium
Python Library and Leaflet maps (http://leafletjs.com/).
Folium builds on the data wrangling strengths of the
Python ecosystem and on the mapping strengths of the
Leaflet. Folium visualizes data on an interactive Leaflet
map. It enables the binding of data to a map for choro-
pleth visualizations and Vincent/Vega visualizations as
markers on the map. Clustering image pixels is an im-
portant image segmentation technique. We used the al-
gorithm of Hou et al. [29] who combined DSets
(dominant sets) and DBSCAN (Density-Based Spatial
Clustering of Applications with Noise) to generate the
clusters of arbitrary shapes without any parameter input.
We then assessed geolocation methods. A first experi-
ment was to apply a random anonymization technique
to the data set. We used noise addition by replacing the
last two digits of the geolocation data by a zero value,
which corresponds to blur geolocation data in a 10 by
10 km area [14].
A second set of experiments used a k-anonymization
[26] method. k-anonymity allows the tolerable disclosure
risk to be selected at the outset. For k-anonymity, the
risk of identity disclosure is upper-bounded by 1/k.
ε-Differential privacy can ensure a very low identity and
disclosure (especially for small ε), but at the expense of
an important utility loss. However, k-anonymity does
not protect against attribute disclosure in general (e.g. if
the values of a confidential attribute are very similar in a
group of k records sharing quasi-identifier values). A
common method for complying to the k-anonymity cri-
terion is to generalize values in the quasi-identifiers by
reducing their precision [30]. A release of data has the k-
anonymity property if the information for each person
contained in the release cannot be distinguished from at
least k-1 individuals whose information also appears in
the release. In our context, k stands for the minimal dis-
tinct days of symptoms. Obviously, the number of users
must be greater than one, failing which it is still possible
to identify this person. After a quantitative exploratory re-
search, we gathered users at least by 2 and data at least by
5, which is a method accepted by the EU directive [8, 31].
For k-anonymity, we tested several values of ε on our
data set. We tested data aggregation to get 5 minimum
points from at least 2 users in a circle of 1 km of radius
(ε = 1), 2.5 km (ε = 2.5 km), and 5 km (ε = 5 km). The
haversine formula was used for the calculation of dis-
tances [32] as it determines the great-circle distance be-
tween two points on a sphere, given their longitude and
latitude. This is the method recommended for calculat-
ing short distances by NASA’s Jet Propulsion Laboratory
(https://www.jpl.nasa.gov).
Random anonymization techniques and k-anonymity
were tested first of all on the five “testers” (with their
consent) who used the App for over 200 days. The two
techniques were then tested for confirmation on 518
users who declared more than 30 days of symptoms.
The users declaring 7 to 15 days of VAS were given special
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focus, as they represent the targeted App users. Seven to
15 days of VAS allowed a sufficient number of events and
appeared to be clinically relevant as most AR patients suffer
from 7 to 15 days during the pollen season [33]. We did not
study periods of between 15 and 29 days since the analyses
of the database showed that there was a low number of users
in this category (< 15%) and that the data were very hetero-
geneous (unpublished data). Finally, the two methods were
tested on the users having declared only one day of VAS.
Results
Participants
From December 1st 2015 to November 30th 2017,
93,116 days of VAS were collected from 8535 users.
5428 (60.1%) users in 22 countries were geolocated, cor-
responding to 54,500 (58.5%) days (Tables 1 and 2).
There was no major difference in the users’ geolocation
rates between countries.
Geolocation of users
The geolocation of VAS days collected in Europe is re-
ported in Fig. 2. The plot refers to days of symptoms. The
color code is linked to the number of days reported. When
zooming, we can associate days of symptoms to specific
users (as described in Fig. 3), confirming that geolocation
is an identifying process which is usable worldwide.
Random anonymity
By including a zero value for the last two digits of the
localization data, we could blur the location zone. When
distinct users were close to each other (as in an urban
zone), this process enabled the merging of different VAS
data (of distinct users) in a single location zone. But in
areas where only one user was using the App, miles
away from the other closest user, the reported VAS data
was linked only to this individual user at that location
(Fig. 3). In these circumstances, the random method by
noise addition did not enable the dissociation of the VAS
data days from their owner. Figure 3a and b show data
collected on one of the five “testers”.
Figure 3b shows the data collected from one of the five
“testers” when the random method by noise addition has
been considered. It shows that it does not enable the
dissociation of the VAS data days from their owner.
Even if it is not possible to determine the precise loca-
tion of the user, it is possible to infer his/her main
Fig. 1 Geolocation using the ISO/TC211 standards (example: Peercode tester position)
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location. The point is now located at the barycentre of
all the previous locations. This method was tested on
the three data subsets that were analyzed. We observed
that 70% of the users declared symptoms within a circle
of 1 to 9 km. This method is therefore not a
de-identification method in our data set.
Generalization approach using k-anonymity
The k-anonymity algorithm was tested on users accord-
ing to the number of VAS they reported (Table 2).
The k-anonymity property was tested with several ε
parameters and users’ anonymity was respected if (i) the
geolocation data were aggregated by at least 5 by 5 for
two distinct users and (ii) the designated perimeter was
a circle of 5 km in diameter (Fig. 4) for urban zones.
The circle perimeter would be automatically adjusted as
needed by the algorithm to fit the first condition (aggre-
gate at least 5 distinct data corresponding to at least 2
different users). If we reconsider the example of the “tes-
ters”, the algorithm could merge the data of another user
to create a location zone big enough to merge the data
of two distinct users. We used the same process with users
having declared more than 30 VAS days or between 7 to
15 VAS days and showed that anonymization was found
for all users. For users having declared only 1 day of VAS,
it is mandatory to merge their geolocation data to at least
one other user in order to de-identify their information.
The algorithm could merge the one VAS day- user’s loca-
tion with up to 5 users if they had all declared only 1 day
of VAS. But even if the users declare only 1 day of VAS,
the k-anonymity method allows the de-identification of
the related results since all the results are aggregated to
get a virtual position as the barycentre of the circle.
This method does not alter the initial quality of the
VAS data but creates a location zone big enough to re-
spect users’ privacy. When more users are identified in
this area, the algorithm will be automatically adjusted to
create a sharper location zone to fit the above condition.
Below is an example of k-anonymity applied to the
users of Valenciennes (France). The circle is calculated
to gather 5 data of at least 2 distinct users. This creates
a circle of 2.5 km of radius that provides an artificial
location at the centre of the circle for each data.
Discussion
The present study in 5428 users from 22 countries showed
that the precision of the geolocation data transferred by
the smart phone is useful and reliable. The privacy of geo-
location was evaluated by two methods, first on the five
“testers” then on the 518 users declaring more than
30 days of VAS, and also in a sample of 234 users report-
ing 7 to 15 days of VAS. Special attention was also paid to
users declaring VAS data only once. k-anonymity ap-
peared to be relevant for data privacy of the Allergy Diary.
Discussion of methods
The General Data Protection Regulation (GDPR) still
recognizes quantification and gradation of anonymiza-
tion methods.
For the Allergy Diary App, pseudonymizing cannot be
considered as an anonymization technique because
linking information data sets (such as pollen exposure)
cannot guarantee that the initial sensitive data will not
be recovered [23].
For random approaches (i) Permutation of data was
not considered, as it would alter the quality of the data-
base (DB); (ii) Differential confidentiality would imply
the calculation of an aggregation estimator on sensitive
data. We did not investigate this option since the DB
could no longer be used to fit the MASK project objec-
tives; (iii) Noise addition was tested. Using a zero value
for the two last digits of the geolocation data, we were
Table 1 World-wide repartition of geolocated days and users
Country Nb of geolocalized data Nb of geolocalized users
AT 1323 200
AU 354 45
BE 398 63
BR 2553 489
CA 66 11
CH 661 238
CZ 101 5
DE 4416 309
DK 485 54
ES 4043 283
FI 1305 167
FR 2206 316
GB 3168 278
GR 1583 89
IT 8500 706
LT 4073 211
MX 9707 496
NL 1304 218
PL 2300 300
PT 4819 810
SE 639 62
TR 496 78
Total 54,500 5428
Table 2 Online: repartition of VAS geolocated days and users
included in the evaluation
VAS days of reporting 1 2–6 7–15 16–30 > 30
Number of users 2273 2311 234 92 518
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able to blur geolocation data in a 10 by 10 km area.
Nevertheless, in our data set, some isolated users were
still identifiable (Fig. 3).
Using k-anonymity, we tested several values of ε on
our data set, and especially on the data collected for
users registering 7 to 15 VAS days, these being our
expected App user profiles. Users’ anonymization
could always be obtained for a circle of 5 km in
diameter. Interestingly, a 5 km circle would blur the
localization data which is better than deleting the last
two digits of the corresponding data in the noise
addition approach (for example in Valenciennes as in
Fig. 4). More generally, the algorithm can automatic-
ally adjust the radius of the circle when needed in
order to fit the appropriate conditions (the k number
of users and data).
We did not study any other generalization approaches.
For instance, l-diversity [13] is an extension of the
k-anonymity method but would imply the consideration
of l distinct values, which is not possible in our data set.
t-proximity [13] is even more stringent than the
k-anonymity and l-diversity methods but we would need
to know the general distribution of the sensitive data.
This method would also imply the segregation of the
data to obtain homogenous distribution classes. These
data treatments would be too restrictive, and the overall
DB quality would be affected.
The general strengths and weaknesses of the tools
should be compared in terms of the three basic require-
ments proposed by WP29 [13] (Table 3).
k-anonymity applied to the MASK DB is sufficient to
guarantee the users’ anonymity, not only on the current
medical data set but also considering the integration of
environmental data sets (e.g. pollen counts and pollution
risks) yet to be gathered. No other DB containing per-
sonal data will be merged to our current data set in the
future for the allergic rhinitis worldwide survey.
We therefore recommend the k-anonymization method
(with our selected conditions/parameters) to anonymize
this kind of geolocated medical data since this method
does not interfere with the overall DB quality. This post
treatment of sensitive data is an irreversible way of
de-identifying the data collected through the App. The
individualization of data is therefore respected, since even
with k = 2, the probability of getting 5 days of identical
VAS values is extremely low and, so far, has never been
observed in our dataset. Considering the other data col-
lected in our DB (such as the impact of allergic symptoms
on daily activities), no correlation is possible with other
data sets. Even if we integrate pollen counts and pollution
risks, no personal data will be added to our database that
could question the anonymization of our data set. Finally,
interference (induction of sensitive information on any
user) is impossible.
Fig. 2 Geolocation of VAS days collected in Europe
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Perspectives
Privacy of information is an increasing concern with the
availability of large amounts of data from many individuals.
In the Allergy Diary App, the mandatory data retrieved to
use the app only include age, sex and country of living.
This information is essential for adjusting the list of treat-
ments available in the country of living. This is why the
privacy concern has to focus only on geolocation data. In
the future, we plan to apply our de-identification method,
allowing us to merge our database with other sources of
information that include precise geolocation data (for ex-
ample: pollen and pollution exposition), while respecting
users’ life privacy. These results are applicable to other DBs
using geolocated data for any field of medicine.
The DB anonymization of “trajectories” (i.e. time and
position information) will be considered as the number
of users increases as well as the duration of the
reporting. We will then consider anonymizing the data
at the export phase (for analysis) with clusters of trajec-
tories [34].
Fig. 3 a VAS data of a single “tester”. b Geolocation data treatment with random method blurs, here only one user’s data
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Guidelines are based on the assumption that patients
regularly use their treatment and that recommendations
are not tested with real-life data. Moreover, for many ques-
tions, recommendations are uncertain. Next-generation
guidelines will need to use anonymized real-life data opti-
mally retrieved using mobile technology to fill the current
gaps. The results of this paper will then be used for guide-
line development.
Conclusions
k-anonymity is an acceptable method for the anonymiza-
tion of MASK data. It can also be used in other medical
app-collected DBs in any fields of medicine. The
remaining risk of identification is quite acceptable when
considering the “reasonable means” [8, 31] used for
re-identification with regards to the Recital 26 GDPR
[11]. This k-anonymization method will be used for all
data collected through the MASK project and this
process will be written in the users’ legal document
(“Terms of Use”/“Privacy Policy”). The post treatment of
personal data is therefore considered to be compatible
with the information given to the users when installing
the App on their personal phone.
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